FibroBiologics, Inc. Receives Nasdaq Delisting Notice

What Happened FibroBiologics, Inc. (FBLG) announced on July 24, 2026 that it received a Staff Determination from Nasdaq on July 22, 2026 notifying the company that Nasdaq staff has determined to delist its securities from The Nasdaq Capital Market. Nasdaq found the company’s bid price closed below $1.00 for 30 consecutive business days (June 8, 2026 through July 21, 2026), putting the company out of compliance with Nasdaq Listing Rule 5550(a)(2). Nasdaq also stated FBLG is ineligible for the normal 180-day compliance period because the company completed a reverse stock split within the prior year (Nasdaq Listing Rule 5810(c)(3)(A)(iv)). Unless appealed, Nasdaq planned to suspend trading at the open on July 31, 2026.

Key Details

• Nasdaq determination date: July 22, 2026; filing dated July 24, 2026 (8-K, Item 3.01).
• Deficiency: closing bid < $1.00 for 30 consecutive business days (June 8–July 21, 2026).
• No 180-day cure period due to recent reverse stock split (Rule 5810(c)(3)(A)(iv)).
• Appeal deadline: company must request a hearing by July 29, 2026 to stay delisting; suspension scheduled July 31, 2026 if no timely appeal.
• The company intends to request a Nasdaq Hearing Panel review and will present a plan to regain compliance; no assurance of success.

Why It Matters A Nasdaq delisting determination is material for investors because it can lead to a trading suspension or the security moving to a less liquid marketplace (e.g., OTC), which often reduces liquidity and can affect share value and the company’s ability to raise capital. FBLG’s immediate next step is an appeal that will temporarily halt delisting while the hearing process proceeds, but the filing makes clear there is no guarantee the company will prevail or regain compliance. Investors should monitor the appeal outcome, any plan to increase the stock price above $1.00, and further filings for updates.